The company emerged Bioaptus of opportunity identified in the laboratory medicine market in Brazil: the supply of monoclonal antibodies. About 99% of the antibodies
used for diagnosis and treatment of diseases in Brazil are imported.
The Bioaptus developed a technology which allows the production of antibodies without the use of cells or immunization of animals.
This is the ANFITECH® Platform, a synthetic antibody that behaves similarly to monoclonal antibodies. Our company is a pioneer in this sector.